Summary
Over the past 30 years the identification of high blood pressure and hypercholesterolaemia as major predictors of cardiovascular disease has led to an increasing expenditure on healthcare costs in pharmacological treatment of these risk factors. Most of the cost has been due to antihypertensive treatment, but evidence from randomised trials of the benefits of cholesterol-lowering drugs, along with the introduction of therapies with fewer side effects, suggests that expenditure on cholesterol treatment will rise dramatically. Cost-effectiveness analyses can aid decision making in the use of these treatments.
For both hypertension and hypercholesterolaemia, the most favourable cost-effectiveness ratios were found in late middle age, in men compared to women, at the highest level of the risk factor, and in subjects with multiple risk factors. The most cost-effective treatments appear to be those which were the cheapest and which also produced the largest reductions in the risk factor. However, certain findings were based on assumptions which may be invalid. The most important of these in hypertension, and to a lesser extent in hypercholesterolaemia, is that different treatments have similar effects on morbidity and mortality for a given level of risk reduction. Experimental evidence that might confirm or refute this is not available for most treatments of hypertension. Moreover there are no trials in women or in the elderly of cholesterol-lowering treatments. The burden of disease due to these risk factors has been underestimated, and further research is required to establish the benefits of treatment on prevention of conditions such as heart failure, peripheral vascular disease, and vascular dementia.
Similar content being viewed by others
References
Amery A, Birkenhäger W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1: 1349–1354, 1985
Amery A, Birkenhäger W, Bulpitt CJ, et al. Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly — objectives, protocol and organization. Aging 3: 287–302, 1991
Assman G, Schulte H. Primary prevention of coronary heart disease in the Federal Republic of Germany: a cost effectiveness Analysis, in Lewis B & Assman G (Eds) The social and economic contexts of coronary prevention, pp. 37–56, Current Medical Literature Ltd, London, 1990.
Bootman JL, Townsend RJ and McGhan WF. Principles of Pharmacoeconomics. Harvey Whitney Books Company, Cincinnati, 1991
Bulpitt CJ, Fletcher AE. Economic assessments in randomized controlled trials. Medical Journal of Australia 153: Sl6–S19, 1990
Castelli WP, Wilson PWF, Levy D, Anderson K. Cardiovascular risk factors in the elderly. American Journal of Cardiology 63: 12H–19H, 1989
Collins R, Peto R, MacMahon S, Herbert P, Fiebach NH, et al. Blood pressure, stroke and coronary heart disease. Part 2, short term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 335: 827–838, 1990
Consensus Statement. Blood cholesterol measurement in the prevention of coronary heart disease. The Sixth King’s Fund Forum, London, 1988
Drummond MF. Principles of economic appraisal in health care, Oxford Medical Publications, Oxford, 1980
Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford Medical Publications, Oxford University Press, Oxford, 1987
Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, et al. Long term cost effectiveness of various initial monotherapies for mild to moderate hypertension. Journal of the American Medical Association 263: 407–413, 1990
Euroqol Group. Euroqol — a new facility for the measurement of health related quality of life. Health Policy 16: 199–208, 1990
Fletcher A. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. Editorial Review. Journal of Hypertension 9: 193–198, 1991a
Fletcher AE. Cost effectiveness analyses in the treatment of high blood pressure: report of the World Hypertension League Workshop on the Economics of Hypertension Control, Barcelona, 27–28 September, 1991. Journal of Human Hypertension, in press, 1991b
Freund DA, Dittus RS. Principles of PE analysis of drug therapy. PharmacoEconomics 1(1): 20–32, 1992
Gallup G Jr, Cotugno HE. Preferences and practices of Americans and their physicians in antihypertensive therapy. American Journal of Medicine 81(6C): 3–8, 1986
Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. Journal of the American Medical Association 265: 1145–1151, 1991
Grimm RH. Epidemiological and cost implications of antihypertensive treatment for the prevention of cardiovascular disease. Journal of Human Hypertension 3 (Suppl. 2): 55–61, 1989
Harris T, Cook E, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. Journal of the American Geriatrics Society 36: 1023–1028, 1988
Hiroyash I, Jacobs DR, Wentworth D, Neaton J, Cohen JD, for the MRFIT Research Group. Serum cholesterol levels and six year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. New England Journal of Medicine 320: 904–910, 1989
Hjalte K, Lidgren B, Persson U, Olsson AG. Lipid lowering therapy: cost estimates in Sweden. in Lewis B & Assman G (Eds) The social and economic contexts of coronary prevention, pp. 76–84, Current Medical Literature Ltd, London, 1990
IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). Journal of Hypertension 3: 379–392, 1985
Kawachi I, Malcolm LA. The benefits of treating mild to moderate hypertension: a quantitative estimation of the life expectancy gains from pharmacological reduction of blood pressure. Journal of Clinical Epidemiology 42: 905–912, 1989
Kawachi I, Malcolm LA. The cost effectiveness of treating mild to moderate hypertension: a reappraisal. Journal of Hypertension 9: 199–208, 1991
Kinosian BP, Eisenberg JM. Cutting into cholesterol. Journal of the American Medical Association 259: 2249–2254, 1988
Leitch D. Who should have their cholesterol concentration measures? What experts in the United Kingdom suggest? British Medical Journal 298: 1615–1616, 1989
McMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomised controlled trials. Progress in Cardiovascular Diseases 29 (Suppl. 1): 99–118, 1986
Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British Medical Journal 291: 97–104, 1985
Oster G, Epstein AM. Cost effectiveness of Antihyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. Journal of the American Medical Association 258: 2381–238, 1987
Pauly MV. The changing Health Care Environment. American Journal of Medicine 81(6C): 3–10, 1986
Peto R, Yusuf S, Collins R. Cholesterol lowering trial results in their epidemiologic context. Circulation 72: 451, 1985
Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus? International Journal of Epidemiology 7: 347–358, 1978
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). Journal of the American Medical Association 265: 3255–3264, 1991
Shimamoto J, Komachi Y, Inada H, et al. Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation 79: 503–515, 1989
Shulman NB, Martinez B, Brogan D, Carr AA, Miles CG. Financial costs as an obstacle to hypertension therapy. American Journal of Public Health, 76: 1105–1108, 1986
Weinstein MD, Stason WB. Hypertension: a policy perspective. Harvard University Press, Cambridge, 1976
Wilhelmsen L, Berglund G, Elmfedt D, et al. Beta blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. Journal of Hypertension 5: 489–498, 1987
Williams A. Economics of coronary bypass grafting. British Medical Journal 291: 326–329, 1984
World Health Statistics, WHO, Geneva, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fletcher, A.E., Bulpitt, C.J. Pharmacoeconomic Evaluation of Risk Factors for Cardiovascular Disease. Pharmacoeconomics 1, 33–44 (1992). https://doi.org/10.2165/00019053-199201010-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199201010-00008